Cargando…

A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease

BACKGROUND: The lipoprotein-associated phospholipase A(2) inhibitor (Lp-PLA(2)), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD). METHODS: One hundred twenty-four subjects with possible mild AD and with neuroimaging evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maher-Edwards, Gareth, De'Ath, Jeni, Barnett, Carly, Lavrov, Arseniy, Lockhart, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975052/ https://www.ncbi.nlm.nih.gov/pubmed/29854933 http://dx.doi.org/10.1016/j.trci.2015.06.003

Ejemplares similares

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
por: Delaby, Constance, et al.
Publicado: (2021)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ(42,) in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents
por: Kounnas, Maria Z., et al.
Publicado: (2016)

Safety of cerebrospinal ﬂuid drainage in descending and thoracoabdominal aortic replacement surgery
por: Nasir, Afsheen, et al.
Publicado: (2023)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

NGP 555, a γ-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses
por: Kounnas, Maria Z., et al.
Publicado: (2019)

Expanding the scope of health disparities research in Alzheimer's disease and related dementias: Recommendations from the “Leveraging Existing Data and Analytic Methods for Health Disparities Research Related to Aging and Alzheimer's Disease and Related Dementias” Workshop Series
por: Akushevich, Igor, et al.
Publicado: (2023)

A week in the life of a hospital-based dental nurse
por: McCabe, Molly, et al.
Publicado: (2022)

'I work seven days a week: I'm a workaholic!'
por: Quinlan, Kate
Publicado: (2022)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Impacts of Exclusion From Municipal Water Service on Water Availability: A Case Study
por: Lockhart, Sydney, et al.
Publicado: (2020)

Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial
por: Hoscheidt, Siobhan, et al.
Publicado: (2021)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
por: Park, Sun Ah, et al.
Publicado: (2017)

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
por: Lee, Jongmin, et al.
Publicado: (2020)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology
por: Rembach, Alan, et al.
Publicado: (2015)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
por: Mäkitalo, Signar, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease
por: Sweeney, Melanie D, et al.
Publicado: (2015)

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
por: Alexopoulos, Panagiotis, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
por: Westwood, Sarah, et al.
Publicado: (2017)

Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
por: Ahmad, Shahzad, et al.
Publicado: (2020)

Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology
por: Hu, Hao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9nd2ljqukcq1hqvdnogc96a8ef